Skip to main content

Hemorrhage

1
Pipeline Programs
14
Companies
18
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
5100%
+ 15 programs with unclassified modality

Competitive Landscape

12 companies ranked by most advanced pipeline stage

Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
3 programs
1
Oxytocin + normal salinePhase 21 trial
Comparison of Physiological Variables During Blood DonationN/A1 trial
No treatmentN/A1 trial
Active Trials
NCT02029807Completed50Est. Jun 2016
NCT01448694Completed320Est. Sep 2014
NCT06141447Recruiting150Est. Nov 2026
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
7 programs
Prizbind®N/A1 trial
idarucizumabN/AMonoclonal Antibody1 trial
BI 655075PHASE_11 trial
IdarucizumabPHASE_3Monoclonal Antibody1 trial
IdarucizumabPHASE_3Monoclonal Antibody1 trial
+2 more programs
Active Trials
NCT02946931Completed1,402Est. Nov 2020
NCT02798107Withdrawn0Est. May 2019
NCT01955720Completed46Est. Aug 2014
+4 more trials
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
Andexanet alfaN/A1 trial
Active Trials
NCT05898412Completed217Est. Nov 2025
Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
ETV/CPCN/A1 trial
Active Trials
NCT02601339Recruiting70Est. Dec 2026
Merit Medical
Merit MedicalSOUTH JORDAN, UT
1 program
EmboCube Embolization GelatinN/A1 trial
Active Trials
NCT05307783Completed101Est. Apr 2024
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
Infrahepatic inferior vena cava clampingN/A1 trial
Active Trials
NCT00732979Completed152Est. Dec 2011
CSL Seqirus
CSL SeqirusUK - Maidenhead
1 program
Kcentra®N/A
CSL Behring
CSL BehringIL - Bradley
1 program
Kcentra®N/A1 trial
Active Trials
NCT02319460Completed2,238Est. Jun 2020
Autonomous Therapeutics
1 program
Zhi Byed 11N/A1 trial
Active Trials
NCT00147420Completed848Est. Mar 2007
One Biosciences
One BiosciencesFrance - Paris
1 program
Zhi Byed 11N/A
Corza Medical
Corza MedicalChina - Shanghai
1 program
TachoSilPHASE_31 trial
Active Trials
NCT06664775Recruiting116Est. Jun 2026
Takeda
TakedaTOKYO, Japan
1 program
TachoSil®PHASE_31 trial
Active Trials
NCT01192022Completed253Est. May 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Corza MedicalTachoSil
Boehringer IngelheimIdarucizumab
Boehringer IngelheimIdarucizumab
Boehringer Ingelheimidarucizumab
Boehringer Ingelheimidarucizumab
TakedaTachoSil®
Colorado TherapeuticsOxytocin + normal saline
Boehringer IngelheimBI 655075
AstraZenecaAndexanet alfa
Merit MedicalEmboCube Embolization Gelatin
Boehringer Ingelheimidarucizumab
Boehringer IngelheimPrizbind®
Human BioSciencesETV/CPC
CSL BehringKcentra®
Colorado TherapeuticsComparison of Physiological Variables During Blood Donation

Showing 15 of 18 trials with date data

Clinical Trials (18)

Total enrollment: 6,487 patients across 18 trials

A Study to Compare the Efficacy and Safety of TachoSil and Surgicel Original as an Adjunct to Control Mild to Moderate Soft Tissue Bleeding During Surgery

Start: Apr 2025Est. completion: Jun 2026116 patients
Phase 3Recruiting

This Study Looks at the Effects of Idarucizumab in Patients Who Take Dabigatran and Need Emergency Surgery or Are Bleeding

Start: Mar 2018Est. completion: Jul 202019 patients
Phase 3Completed

Reversal Dabigatran Anticoagulant Effect With Idarucizumab

Start: Sep 2016Est. completion: Oct 20191 patients
Phase 3Completed

CU Programme of Idarucizumab for Japanese Patients

Start: Jul 2016Est. completion: Sep 20161 patients
Phase 3Completed

Reversal of Dabigatran Anticoagulant Effect With Idarucizumab

Start: May 2014Est. completion: Oct 2016503 patients
Phase 3Completed

TachoSil® Versus Surgicel® Original for the Secondary Treatment of Local Bleeding in Adult and Pediatric Patients Undergoing Hepatic Resection Surgery

Start: Aug 2010Est. completion: May 2013253 patients
Phase 3Completed
NCT06141447Colorado TherapeuticsOxytocin + normal saline

Changes in Hemorrhage With Prophylactic Oxytocin for Dilation and Evacuation

Start: May 2024Est. completion: Nov 2026150 patients
Phase 2Recruiting

Safety, Tolerability, PK and PD of BI 655075 and Establishment of BI 655075 Dose(s) Effective to Reverse Prolongation of Blood Coagulation Time by Dabigatran

Start: Sep 2013Est. completion: Aug 201446 patients
Phase 1Completed

Retrospective Study on Characteristics and Outcomes in Hospitalised Patients Treated With Ondexxya

Start: Oct 2023Est. completion: Nov 2025217 patients
N/ACompleted
NCT05307783Merit MedicalEmboCube Embolization Gelatin

EmboCube Gelatin Embolization to Control Bleeding or Hemorrhaging

Start: Nov 2022Est. completion: Apr 2024101 patients
N/ACompleted

Observational Study to Evaluate Safety of Idarucizumab in Pediatric Patients

Start: May 2019Est. completion: May 20190
N/AWithdrawn

All-Case Surveillance of Prizbind®

Start: Nov 2016Est. completion: Nov 20201,402 patients
N/ACompleted

NIRS Monitoring in Premature Infants

Start: Apr 2015Est. completion: Dec 202670 patients
N/ARecruiting

An Observational Cohort Study to Investigate the Risk of Thromboembolic Events in Patients Receiving Kcentra® or Plasma to Reverse Vitamin K Antagonist (VKA) Therapy in the Setting of Acute Major Bleeding

Start: Apr 2014Est. completion: Jun 20202,238 patients
N/ACompleted
NCT02029807Colorado TherapeuticsComparison of Physiological Variables During Blood Donation

Comparison of Physiological Variables During Blood Donation

Start: Jan 2014Est. completion: Jun 201650 patients
N/ACompleted

Non-invasive Hemodynamic Monitoring During Blood Donation for Developing Models of Early Blood Loss

Start: Nov 2011Est. completion: Sep 2014320 patients
N/ACompleted
NCT00732979Heidelberg PharmaInfrahepatic inferior vena cava clamping

Infrahepatic Inferior Vena Cava Clamping During Hepatectomy

Start: Mar 2008Est. completion: Dec 2011152 patients
N/ACompleted

RCT of Zhi Byed 11 (ZB11) Versus Misoprostol in Tibet

Start: Sep 2005Est. completion: Mar 2007848 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 actively recruiting trials targeting 6,487 patients
14 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.